Clinical Trial Update: Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent Head and Neck Cancer [Phase 1]

View source ↗

Summary

This document reports the completion of a Phase 1 pilot study evaluating the combination of cetuximab with the Hedgehog pathway inhibitor IPI-926 (saridegib) in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Erbitux (cetuximab) (cetuximab)
• saridegib (saridegib)

Snippet

Sponsor: University of Colorado, Denver | Conditions: Recurrent Head and Neck Cancer | Phase 1 | Status: COMPLETED